Corporate Profile

Arena is a clinical-stage biopharmaceutical company committed to discovering and developing innovative therapies offering significant medical advances and new options for patients. We are focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Our lead drug candidate, lorcaserin hydrochloride, is intended for the treatment of obesity and is being evaluated in a Phase 3 clinical trial program. Our broad pipeline of novel compounds target G protein-coupled receptors (GPCRs), an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc. and Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Featured Report

2008 Interactive Annual Report

Stock Information